Skip to content
approvedWeight Loss & Diabetes

Lixisenatide

Also known as: Adlyxin, Lyxumia, AVE0010

Lixisenatide is a once-daily short-acting GLP-1 receptor agonist derived from exendin-4 with a modified C-terminus for enhanced potency. FDA-approved in 2016 as Adlyxin, it primarily targets postprandial glucose excursions through potent gastric emptying delay. The ELIXA cardiovascular outcomes trial confirmed cardiovascular safety in patients with recent acute coronary syndrome.

4 cited references·5 researched benefits

Quick Answer

Lixisenatide (Adlyxin/Lyxumia) is a once-daily injectable GLP-1 receptor agonist based on exendin-4, FDA-approved for type 2 diabetes in 2016. It provides strong postprandial glucose control through delayed gastric emptying and is the only short-acting GLP-1 RA tested specifically in post-acute coronary syndrome patients (ELIXA trial). It reduces HbA1c by 0.7–0.9% and is available in a fixed-ratio combination with insulin glargine (Soliqua).

Key Facts

Mechanism
Lixisenatide is a 44-amino-acid peptide derived from exendin-4 with deletion of proline at position 38 and addition of six lysine residues at the C-terminus to increase DPP-4 resistance and binding affinity. As a short-acting GLP-1 RA, its predominant effect is pronounced gastric emptying delay (reducing postprandial glucose spikes by 4–5 mmol/L) rather than sustained GLP-1 receptor activation. It binds pancreatic beta-cell GLP-1 receptors to enhance glucose-dependent insulin secretion and suppress postprandial glucagon release.
Research Status
approved
Half-Life
~3 hours
Molecular Formula
C₂₁₅H₃₄₇N₆₁O₆₅S
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Postprandial glucose control — reduces postprandial glucose by 4–5 mmol/L, the strongest postprandial effect among GLP-1 RAsstrong
  • HbA1c reduction — lowers HbA1c by 0.7–0.9% across GetGoal clinical trial programstrong
  • Cardiovascular safety — ELIXA trial demonstrated neutral CV outcome in high-risk post-ACS patientsstrong
  • Combination with insulin — Soliqua (lixisenatide + insulin glargine) provides complementary fasting and postprandial glucose coveragestrong
  • Modest weight loss — 1–3 kg weight reduction, primarily through appetite suppression and gastric emptying delaymoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection10–20 mcgOnce dailyInitiate at 10 mcg daily for 14 days, then increase to 20 mcg daily. Inject within 1 hour before first meal of the day. Available as prefilled pen.
Fixed-ratio combination (Soliqua 100/33)15–60 units insulin glargine / 5–20 mcg lixisenatideOnce dailySoliqua combines insulin glargine (100 units/mL) with lixisenatide (33 mcg/mL) in a single injection. Dose titrated based on fasting glucose targets.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea — most common adverse effect (25–30%), typically during first 2–3 weeks and resolving with continued usecommon
  • Vomiting — occurs in 6–10% of patients, more common during dose escalationcommon
  • Headache — reported in 8–11% of patientscommon
  • Hypoglycemia — low risk as monotherapy but increased when combined with sulfonylureas or insulinrare
  • Anaphylaxis — very rare severe allergic reactions have been reported post-marketingserious

Frequently Asked Questions

Why is lixisenatide called a short-acting GLP-1 RA?
GLP-1 RAs are classified as short-acting (lixisenatide, exenatide twice-daily) or long-acting (semaglutide, dulaglutide, liraglutide). Short-acting agents have intermittent receptor activation that primarily delays gastric emptying and targets postprandial glucose. Long-acting agents provide continuous receptor activation, causing tachyphylaxis of the gastric emptying effect but stronger fasting glucose and HbA1c reduction. The distinction affects clinical positioning: lixisenatide excels for patients with predominantly postprandial hyperglycemia.
What is Soliqua and how does it differ from separate injections?
Soliqua 100/33 is a fixed-ratio combination of insulin glargine (basal insulin) and lixisenatide (GLP-1 RA) in a single prefilled pen. It provides complementary glucose control: glargine targets fasting glucose while lixisenatide targets postprandial glucose. The combination reduces HbA1c more than either component alone with less weight gain and hypoglycemia than insulin alone. Patients appreciate the convenience of one daily injection instead of two.
What did the ELIXA trial show about cardiovascular safety?
ELIXA (Evaluation of Lixisenatide in Acute Coronary Syndrome) enrolled 6,068 patients with type 2 diabetes who had experienced a recent acute coronary event (within 180 days). Over a median follow-up of 25 months, lixisenatide showed cardiovascular safety (HR 1.02 for MACE, non-inferior to placebo). While it did not demonstrate cardiovascular benefit like some longer-acting GLP-1 RAs, it confirmed safety in this high-risk population.
Is lixisenatide still widely prescribed given newer GLP-1 RAs?
Lixisenatide market share has declined significantly with the availability of more potent agents like semaglutide and tirzepatide. Its main role now is in the Soliqua combination product, which offers a unique fixed-ratio combination with insulin glargine. As a standalone agent, it remains an option for patients who primarily need postprandial glucose control or who cannot tolerate longer-acting GLP-1 RAs.
How does lixisenatide affect oral medication absorption?
Because lixisenatide significantly delays gastric emptying, it can slow the absorption of orally administered medications. Drugs requiring rapid absorption or with a narrow therapeutic index should be taken at least 1 hour before or 11 hours after lixisenatide injection. Antibiotics and oral contraceptives should be taken at least 1 hour before the lixisenatide dose for consistent absorption.

References

  1. 1
    Lixisenatide in patients with type 2 diabetes and acute coronary syndrome (ELIXA)(2015)PubMed ↗
  2. 2
    Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes (GetGoal-S)(2013)PubMed ↗
  3. 3
    Insulin glargine/lixisenatide fixed-ratio combination versus insulin glargine and lixisenatide alone (LixiLan-O)(2016)PubMed ↗
  4. 4
    Short-acting versus long-acting GLP-1 receptor agonists: a systematic review and meta-analysis of cardiovascular outcomes(2019)PubMed ↗

Latest Research

Last updated: 2026-02-19